Cargando…

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

INTRODUCTION: Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis (MS) treated with peginterferon beta-1a. The purpose of this Delphi analysis was to explore peginterferon beta-1a discontinuation rates across MS treatment cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Sarah, Harris, Colleen, Allan, Michelle, Chieffe, Carol, Eelen, Piet, Röder, Claudia, Mouzawak, Catherine, Naylor, Maria L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140009/ https://www.ncbi.nlm.nih.gov/pubmed/33761099 http://dx.doi.org/10.1007/s40120-021-00238-3

Ejemplares similares

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
por: Newsome, Scott D., et al.
Publicado: (2018)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
por: Zhao, Yuan, et al.
Publicado: (2021)

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
por: Scott, Thomas F, et al.
Publicado: (2016)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function
por: Cortés-Telles, Arturo
Publicado: (2016)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

What establishes an excellent nurse? A focus group and Delphi panel approach
por: Paans, Wolter, et al.
Publicado: (2017)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
por: Menge, Til, et al.
Publicado: (2021)

Peginterferon based therapy for chronic hepatitis C in the elderly patients
por: Bold, Adriana, et al.
Publicado: (2013)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Best Practice Guidelines for Hip Arthroscopy in Femoroacetabular Impingement: Results of a Delphi Process
por: Lynch, Thomas Sean, et al.
Publicado: (2019)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
por: El Raziky, Maissa, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013)

Development and Delphi validation of a Best Possible Medication History form
por: Hoornaert, Camille, et al.
Publicado: (2023)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
por: Li, Wen-cong, et al.
Publicado: (2011)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
por: Arnold, Douglas L., et al.
Publicado: (2018)

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device
por: Varunok, Peter, et al.
Publicado: (2011)

Research priorities for respiratory nursing: a UK-wide Delphi study
por: Kelly, Carol Ann, et al.
Publicado: (2018)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
por: Arnold, Douglas L., et al.
Publicado: (2017)

OSCE best practice guidelines—applicability for nursing simulations
por: Kelly, Michelle A., et al.
Publicado: (2016)

Measurement of $\alpha_s$ and the $\beta$ function with the DELPHI detector at LEP
por: Passon, Oliver
Publicado: (2003)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
por: El-Lababidi, Rania M., et al.
Publicado: (2020)

Interferon-alpha-2a/peginterferon: Various toxicities: 6 case reports
Publicado: (2022)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
por: Chen, Shao-Long, et al.
Publicado: (2023)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qo9bc1thj8bo1qal7m06hu7o6b